| Fri, 23 Jun 2017 13:46:18: | Bluebird Bio rebuilds case for blood disorder gene therapy
|
| Fri, 23 Jun 2017 12:45:58: | Aveo soars as long-beleaguered cancer drug nears approval
|
| Fri, 23 Jun 2017 09:12:53: | Novartis-backed GenSight gets cash for gene therapy launch
|
| Thu, 22 Jun 2017 13:14:34: | EuroBiotech: More Articles of Note
|
| Thu, 22 Jun 2017 12:59:20: | Biotech bounces as the bones of Trump's plans on pricing emerge
|
| Thu, 22 Jun 2017 12:19:15: | Seven years after Merck deal, ElexoPharm offloads aldosterone synthase inhibitors to Angion
|
| Thu, 22 Jun 2017 09:54:06: | Eli Lilly completes expansion of San Diego biotech center
|
| Thu, 22 Jun 2017 08:16:06: | Celgene-backed cancer biotech Repare emerges from stealth with $68M
|
| Wed, 21 Jun 2017 14:38:52: | Clinigen makes 3 exclusive compassionate-use deals
|
| Wed, 21 Jun 2017 13:16:28: | Vineti scores $13M+, launches cloud-based platform for cell therapies
|
| Wed, 21 Jun 2017 12:46:48: | Sarepta signs another Duchenne gene therapy pact as it aims for wider treatment
|
| Wed, 21 Jun 2017 11:34:31: | Cash-strapped ImmunoCellular halts brain cancer vaccine trial, eyes 'strategic alternatives'
|
| Wed, 21 Jun 2017 10:25:42: | Gottlieb’s FDA to rethink targeted therapy regulation to speed development, drive down healthcare costs
|
| Wed, 21 Jun 2017 08:19:40: | Apple Tree helps Big Apple biotech Syntimmune in $50M series B
|
| Tue, 20 Jun 2017 15:21:37: | Flagship-backed Rubius raises $120M to take off-the-shelf red blood cell cancer therapeutics into the clinic
|
| Tue, 20 Jun 2017 13:54:52: | Merck Ventures, CRUK launch new immuno-oncology spinout biotech iOnctura
|
| Tue, 20 Jun 2017 12:32:42: | R&D costs growing, Roche shines and Novo high for ROI: It’s the EP report
|
| Tue, 20 Jun 2017 12:10:55: | Ionis’ Akcea closes in on $125M IPO to fund phase 3 trials
|
| Tue, 20 Jun 2017 11:46:43: | Novartis' longer-acting AMD drug matches archrival Eylea in phase 3 trials
|
| Tue, 20 Jun 2017 11:24:11: | Parexel to go private in $5B Pamplona Capital buyout deal
|
| Tue, 20 Jun 2017 10:01:48: | Cell Medica buys clinical-phase WT1-TCR cell therapy
|
| Mon, 19 Jun 2017 13:21:56: | Novartis-backed Gamida Cell gains $40M for phase 3 work
|
| Mon, 19 Jun 2017 12:48:14: | Seattle Genetics stops all trials of '33A blood cancer drug after patient deaths
|
| Mon, 19 Jun 2017 09:01:32: | Woodford invests in Big Pharma-backed dementia fund
|
| Mon, 19 Jun 2017 07:58:14: | Parker-Tessa alliance tees up solid tumor I-O combinations
|
